R&D

SAFA is expandable to
diverse pipelines

  • home
  • R&D
  • Technology

SAFA PLATFORM

SAFAbody™

Meet Aprilbio’s unique albumin
binder fusion technology

What’s so good about it?
  • Exclusivity

    Own exclusive right of use

  • Distinction

    Advantageous for anti-cancer or inflammation treatments as it leads drugs to cancerous or affected areas

  • Expandability

    Appliable to antibodies, cytokines, and many more and capable of developing bispecific targets

  • Adverse Effect

    Human antibody designed, low in immunogenicity and minimized in adverse effects

  • Half-life

    SAFA-applied drugs may maintain for as long as albumin stays in human bodies: 19 days

SAFA-PATENT REGISTERED
-
WO/2015/030539 “AN ANTI SERUM ALBUMIN FAB-EFFECTOR MOIETY FUSION CONSTRUCT, AND THE PREPARING METHOD THEREOF”, published in 2015
-
The patent was registered in Republic of Korea (10-1576561), USA (US9879077), China (105899532), EU (3039038), Japan (2016-538860), Canada (2922618), Colombia (33196), Russia (P-787/3RU), Ukraine (8591/3A/18), Philippine (1/2016/500403), India (201617007424 ), and etc.

Platform Technology

SAFA TECHNOLOGY

Extending the plasma half-life of recombinant biological drugs

What is SAFA?

anti-Serum Albumin Fab-Associated

  • STEP 01
    High affinity anti-SA Fab from HuDVFab library (SL335)
  • STEP 02
    Determination of therapeutic effector proteins (Ab fragments, cytokines or hormones)
  • STEP 03
    Production of fusion proteins by using gene cloning and protein expression system
  • STEP 04
    In vivo administration of a fusion protein binding of fusion protein to SA in the body
  • STEP 05
    Prolonged serum half-life of a SAFA fusion protein drug
  • STEP 01
    High affinity anti-SA Fab from HuDVFab library (SL335)
  • STEP 02
    Determination of therapeutic effector proteins (Ab fragments, cytokines or hormones)
  • STEP 03
    Production of fusion proteins by using gene cloning and protein expression system
  • STEP 04
    In vivo administration of a fusion protein binding of fusion protein to SA in the body
  • STEP 05
    Prolonged serum half-life of a SAFA fusion protein drug

Serum albumin (SA)

Long serum half life (~19 days) via FcRn recycling mechanism

VERSATILITY OF Aprilbio’s
PLATFORM Technology

Diverse & unique pipelines can be developed by

TWO PROPRIETARY PLATFORM TECHNOLOGIES
Unique features